Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Share-based Payment Arrangement [Abstract]

Schedule of non-cash share-based compensation expense

Non-cash share-based compensation expense, consisting of expense for stock options, Restricted Share Units ("RSUs") and Employee Share Purchase Plan ("ESPP"), was classified in the condensed consolidated statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development expenses	$	5,250	$	3,638	$	17,927	$	17,668
Selling, general and administrative expenses	9,315		6,333		25,279		17,187
	$	14,565	$	9,971	$	43,206	$	34,855
Less: Share-based compensation expense attributable to non-controlling interests	$	(1,439)	$	—	$	(1,439)	$	—
Share-based compensation expense attributable to Biohaven Pharmaceutical Holding Company Ltd.	$	13,126	$	9,971	$	41,767	$	34,855

Schedule of stock option activity

The following table is a summary of the Company's stock option activity for the nine months ended September 30, 2020:

	Number of Shares	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at December 31, 2019	9,423,015	$24.58
Granted	311,338	$53.60
Exercised	(1,700,357)	$11.69
Forfeited	(87,876)	$42.32
Outstanding at September 30, 2020	7,946,120	$28.28	7.23	$	292,267
Options exercisable at September 30, 2020	4,474,848	$20.13	6.43	$	200,903
Vested at September 30, 2020 and expected to vest in the future	7,946,120	$28.28	7.23	$	292,267

Schedule of RSU activity

The following table is a summary of the RSU activity for the nine months ended September 30, 2020:

	Number of Shares	Weighted Average Grant Date Fair Value
Unvested outstanding as of December 31, 2019	88,950	$57.40
Granted	499,525	$55.14
Forfeited	(11,957)	$54.30
Vested	(90,258)	$56.10
Unvested outstanding as of September 30, 2020	486,260	$55.40